SCHEMBL5359737

SCHEMBL5359737

Clc1ccc(-c2ccc(C3(c4ccc(-c5ccc(Cl)cc5)cc4)c4cc(Br)ccc4-c4ccc(Br)cc43)cc2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 3/20 0.38
TDP2 O95551 2/20 0.37
MDM2 Q00987 3/20 0.37
MCL1 Q07820 2/20 0.36
KMT2A Q03164 2/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
AHR P35869 1/20 0.34
MGAM O43451 1/20 0.34
GAA P10253 1/20 0.34
SI P14410 1/20 0.34
MGAM2 Q2M2H8 1/20 0.34
GCGR P47871 1/20 0.33
MAPK14 Q16539 1/20 0.33
CYP1A2 P05177 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24257780 0.89 PDK2 (0.46) PDK2TDP2MCL1KMT2ALMNA
SCHEMBL26050356 0.89 PDK2 (0.46) PDK2TDP2MCL1KMT2ALMNA
SCHEMBL5355996 0.89 PDK2 (0.39) PDK2TDP2KMT2ALMNAMAPT
SCHEMBL12635475 0.84 MAPK1 (0.48) PDK2TDP2MCL1KMT2ALMNA
SCHEMBL31495788 0.84 MEN1 (0.45) PDK2MDM2KMT2ALMNAMAPT
SCHEMBL26050362 0.83 PDK2 (0.41) PDK2TDP2MDM2MCL1KMT2A
SCHEMBL14521000 0.83 PDK2 (0.42) PDK2TDP2MCL1KMT2ALMNA
SCHEMBL27043784 0.82 MAPT (0.46) PDK2MDM2KMT2ALMNAMAPT
SCHEMBL20690840 0.81 PDK2 (0.41) PDK2KMT2ALMNAMAPTSMN1; SMN2
SCHEMBL16922978 0.81 MAPK1 (0.45) PDK2TDP2MCL1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7189877-B2 Arylamine derivatives having fluorene skeleton, synthetic intermediates thereof, processes of producing those, and organic electrolumivescene devices TOSCH CORPORATION (JP) 2007-03-13 US disclosed
US-7189877-B2 Arylamine derivatives having fluorene skeleton, synthetic intermediates thereof, processes of producing those, and organic electrolumivescene devices TOSCH CORPORATION (JP) 2007-03-13 US disclosed
US-7189877-B2 Arylamine derivatives having fluorene skeleton, synthetic intermediates thereof, processes of producing those, and organic electrolumivescene devices TOSCH CORPORATION (JP) 2007-03-13 US disclosed
EP-1400578-B1 Electrolumisescent 9,9-bis(4-amino)-1,1'-biphenyl)fluorene derivatives TOSOH CORP (JP) 2005-11-30 EP disclosed
US-20040110958-A1 Novel arylamine derivatives having fluorene skeleton, synthetic intermediates thereof, processes of producing those, and organic electrolumivescene devices TOSOH CORPORATION 2004-06-10 US disclosed
EP-1400578-A1 Electrolumisescent 9,9-bis(4-amino)-1,1'-biphenyl)fluorene derivatives Tosoh Corporation (JP) 2004-03-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110958-A1 Novel arylamine derivatives having fluorene skeleton, synthetic intermediates thereof, processes of producing those, and organic electrolumivescene devices AHR, NAT1, AR PDK2 2093/4885TDP2 4500/4885MDM2 2670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.